All medicine sold in the European Union must have the product name in braille on the packaging. Likewise, the patient information leaflet (found inside the medicine package) must be made available in alternative formats. EBU and its network partners are strongly involved in promoting the effective implementation of European Directive 2004/27/EC in an adequate manner across the European Union.
For more information see :
EBU Guidelines on Braille Labelling of Medicinal Products, March 2009
European Commission Guidance concerning the braille requirements for labelling and the package leaflet